September 4, 2025- Zoll® emphasizes the current publication of the European Coronary heart Journal of SCD-Defend, an unbiased scientific research designed to particularly the danger of sudden coronary heart dying (SCD) within the Early Put up-MI/CAD and new NICM interval and new NICM interval (GDMEPIETE) with a directive-oriented).

Essential findings about 19,598 consecutive Lifevest WCD sufferers:

• There was a really excessive use of GDMT medicine from 4 Pillaire GDMT when discharged:
  • 81.7% of sufferers had an SGLT2 inhibitor
  • 74.7% of sufferers have been on an Arni
  • 95.1% of sufferers have been on a beta -blocker
  • 83.1% of sufferers had a MRA
• Regardless of a excessive use of GDMT, the pace of appropriate lifefest therapies was excessive:
  • NICM: 6.10 Appropriate therapies per 100 affected person years
  • Mi/CAD: 8.64 Acceptable therapies per 100 affected person years
• The pace of appropriate lifest therapies in SCD Defend was considerably greater than the therapy percentages reported in ICD research of persistent sufferers, indicating that the outcomes of ICD investigations could not apply to the early interval of GDMT.

“4 Pillaire GDMT has proven robust outcomes, however these findings illustrate that there’s a susceptible early interval, whereby the SCD danger stays excessive regardless of an intensive use of GDMT remedy,” mentioned Marat Fudim, MD, MHS, an creator of the SCD Defend research.

“SCD-Defend is a milestone research that reforms our understanding of SCD danger within the context of contemporary GDMT,” Fudim continued. “This knowledge helps the Lifest WCD as an efficient software for shielding newly recognized coronary heart failure and post-Mi sufferers with diminished EF throughout this danger voices.”

SCD Defend contributes to the physique of proof that reinforces the effectiveness of the Lifevest WCD. On this cohort of 19,598 consecutive Actual-World sufferers, the Median LifeVest Put on Time® was 23.4 and 23.5 hours at NICM and MI/CAD sufferers respectively. Inappropriate therapies have been uncommon with a complete pace of 0.5% of sufferers.

Solely Lifevest has> 95% First-Shock Success in Peer-Reviewed Publications and Sensible use, 96% survival knowledge of 1 12 months and a wealth of revealed research for greater than 120,000 sufferers.

Greater than one million men and women are protected by Lifevest, the one WCD with in-network protection for> 98% of the commercially lined lives.12 For extra info, go to www.lifevestinnovation.com.

SCD Defend is an unbiased investigation. View the publication right here and for extra info go to www.scdprotection.com.

Learn the press launch right here.